|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Insulin-like growth favtors (IGFs) and IGF binding proteinsin active Crohn’s disease treated with Q-3 or Q-6 fattyacids and corticosteroids 显示文摘 | Eivindson M Gronbaek H Nielsen JN | 2005 | Scand J Gastroenterol2005，40，10： | 1 |
| 2 | The insulinlike growth factor system and markers of inflammation in adult patients with inflammatory bowel disease显示文摘 | Eivindson M Nielsen JN Grnbaek H | | 0，，01： | 1 |
| 3 | The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease:relations to disease activity and corticosteroid treatment显示文摘 | Eivindson M Gr(o)nbaek H Flyvbjerg A | | 0，，01： | 1 |
| 4 | The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn’s disease显示文摘 | Martin Eivindson Henning Gr?nb?k Kristin Skogstrand Poul Thorsen Jan Frystyk Allan Flyvbjerg Jens F. Dahlerup | 2007 | Scandinavian Journal of Gastroenterology2007，，4： | 1 |
| 5 | The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn’s disease: Relations to disease activity and corticosteroid treatment显示文摘 | Martin Eivindson Henning Gr?nb?k Allan Flyvbjerg Jan Frystyk Erik Zimmermann-Nielsen Jens Frederik Dahlerup | 2006 | Growth Hormone & IGF Research2006，，1： | 1 |
| 6 | Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomized, placebo-controlled, multicentre study 显示文摘 | MURPHY KR EIVINDSON A PAUKSENS K | 2000 | Clin Drug Invest2000，20，1： | 1 |
| 7 | Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease显示文摘 | Murphy KR Eivindson A Pauksens K | 2000 | Clin Drug Invest2000，20，： | 1 |
| 8 | Misdiagnosed amoebic colitis leading to severe dysentery and necrotizing colitis-report of a case and review of the literature显示文摘 | Mogensen TH Christiansen JJ Eivindson MV | 2014 | Scand J of Infect Dis2014，46，3： | 1 |
| 9 | The insulin-like growth factor (IGF) system in active ulcerative colitis and Crohn's disease:Relations to disease activity and corticosteroid treatment显示文摘 | Eivindson M Grφnbaek H Flyvbjerg A | | 0，，01： | 1 |
| 10 | ω-3或ω-6脂肪酸和皮质激素治疗活动性克罗恩病时胰岛素样生长因子及其结合蛋白的表达显示文摘Objective. Catabolism and growth impairment are well-known complications of inflammatory bowel disease (IBD). This may be caused by the disease activity itself and/or the medical treatment, and both may lead to changes in the growth hormone (GH)/insulin-like growth factor I (IGF-I) axis. The aim of the present study was to examine the effects of enteral nutrition. Impact Powder(r), as adjuvant therapy to corticosteroid treatment on changes in the GH/IGF-I axis in patients with Crohn’ s disease (CD). Material and methods. The patients were randomized to 3-IP (ω -3-fatty acid (FA), 3 g/day) or 6-IP (ω -6-FA, 9 g/day). Changes in total IGF-I (tIGF-I) and total IGF-II (tIGF-II), free IGF-I (fIGF-I), IGF binding proteins (IGFBP-1 and IGFBP-3), IGFBP-3 protease activity and insulin levels were examined in 31 patients with active CD (CDAI: 186-603) during treatment with prednisolone (40 mg for 1 week) and tapering the dose by 5 mg/week. Clinical and biochemical markers of inflammation were studied at day 0, and after 5 and 9 weeks. Results. There were no differences at baseline between the two groups. During the treatment period, tIGFI, fIGF-I and IGFBP-3 increased significantly in both groups compared to baseline (p < 0.05) without differences between the groups. Insulin and IGFBP-1 showed no significant changes throughout the treatment period. Conclusions. There was no difference between 3-IP and 6-IP as adjuvant enteral nutrition on the GH/IGF-I axis. The changes observed in the GH/IGFI axis are in line with previously published studies and may be explained by corticosteroid treatment; however, we cannot exclude an additional effect of ω 3-/ω 6 FA as adjuvant enteral nutrition. | Eivindson M. Grbak H. Nielsen J.N. 赵天智 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员